Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRANSCEND-T2D-2 (vs semaglutide 2 mg)

TRANSCEND-T2D-2 (vs semaglutide 2 mg)

Retatrutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
t2d
Official title
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Sponsor
Eli Lilly and Company
Phase
3
Registry status
active not recruiting · 2024-02 → 2026-08
Participants
1250
Duration
80 weeks
Registry
NCT06260722

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
retatrutide 9 mg vs semaglutide 2 mg (active)t2d80—−19.5 %—−2.24.8—21.210.2——press release
retatrutide 12 mg vs semaglutide 2 mg (active)t2d80—−20.9 %—−2.27.9—23.815.0——press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (10)
  • retatrutide 9 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
    Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
  • retatrutide 9 mg · ae_dc · Results, adverse events paragraph
    Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
  • retatrutide 9 mg · nausea · Results, adverse events paragraph
    nausea (21.2%, 23.8% vs. 21.3%)
  • retatrutide 9 mg · vomiting · Results, adverse events paragraph
    vomiting (10.2%, 15.0% vs. 13.2%)
  • retatrutide 9 mg · hba1c · Results, paragraph 2 and efficacy estimand table
    both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.
  • retatrutide 12 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
    Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
  • retatrutide 12 mg · ae_dc · Results, adverse events paragraph
    Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
  • retatrutide 12 mg · nausea · Results, adverse events paragraph
    nausea (21.2%, 23.8% vs. 21.3%)
  • retatrutide 12 mg · vomiting · Results, adverse events paragraph
    vomiting (10.2%, 15.0% vs. 13.2%)
  • retatrutide 12 mg · hba1c · Results, paragraph 2 and efficacy estimand table
    both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRANSCEND-T2D-2 (vs semaglutide 2 mg). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.